Horm Metab Res 2010; 42(5): 318-323
DOI: 10.1055/s-0030-1248304
Original Basic

© Georg Thieme Verlag KG Stuttgart · New York

Measurement of Adiponectin Production from Differentiated Metabolic Stem Cells

Y. Inomata-Kurashiki1 , K. Maeda1 , 2 , E. Yoshioka1 , A. Fukuhara1 , A. Imagawa1 , M. Otsuki1 , I. Shimomura1
  • 1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
  • 2Complementary and Alternative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
Further Information

Publication History

received 06.10.2009

accepted 28.01.2010

Publication Date:
10 March 2010 (online)


To treat metabolic syndrome, fat tissue dysfunction should be corrected rather than controlling conventional risk factors such as hypertension, dyslipidemia, and diabetes mellitus. For this purpose, accumulating evidence suggests increasing plasma adiponectin levels can be a key treatment strategy, especially in setting of food or drug selection. Here we report that adipocyte precursors obtained from several sites of fat tissue, which we call Metabolic Stem Cells (MSC), could be used as a novel screening system to identify adiponectin enhancing drugs or food for individual patients. MSC were prepared from fat tissues collected from 29 patients. They were differentiated in cultures into mature adipocytes. The time course of adiponectin production was independent of the number of mature adipocytes and gradually decreased at 48 h after differentiation. Pioglitazone, a full PPARγ agonist, stabilized adiponectin production at days 8–16 after differentiation, whereas telmisartan, a partial PPARγ agonist, showed variable response. Dividing the adiponectin secretion of day 12 by that of day 10 provided an estimate of adiponectin-producing activity irrespective of the number of MSC-derived adipocytes in culture. Using this score of adiponectin-production activity, we successfully assessed 16 agents in a 96-well plate. The effect of each agent on adiponectin production showed a similar pattern, independent of the site of isolated adipose tissue. Our results show that MSC can be used as a tool for selecting drugs that enhance adiponectin-production activity.



K. Maeda, MD 

Department of Metabolic Medicine

Graduate School of Medicine

Osaka University

2-2 Yamadaoka, Suita

565-0871 Osaka


Phone: +81/6/6879 3732

Fax: +81/6/6879 3739

Email: [email protected]